0001209191-17-067392.txt : 20171227
0001209191-17-067392.hdr.sgml : 20171227
20171227140702
ACCESSION NUMBER: 0001209191-17-067392
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171222
FILED AS OF DATE: 20171227
DATE AS OF CHANGE: 20171227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shames Richard S.
CENTRAL INDEX KEY: 0001675878
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37852
FILM NUMBER: 171275898
MAIL ADDRESS:
STREET 1: C/O PROTAGONIST THERAPEUTICS, INC.
STREET 2: 521 COTTONWOOD DRIVE, SUITE 100
CITY: MILPITAS
STATE: CA
ZIP: 95035
FORMER NAME:
FORMER CONFORMED NAME: Shame Richard S
DATE OF NAME CHANGE: 20160527
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc
CENTRAL INDEX KEY: 0001377121
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980505495
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
BUSINESS PHONE: (510) 474-0170
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Therapeutics Inc
DATE OF NAME CHANGE: 20130605
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Inc
DATE OF NAME CHANGE: 20061002
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-22
0
0001377121
Protagonist Therapeutics, Inc
PTGX
0001675878
Shames Richard S.
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BOULEVARD, SUITE 140
NEWARK
CA
94560
0
1
0
0
Chief Medical Officer
Common Stock
2017-12-22
4
M
0
3529
4.21
A
3529
D
Common Stock
2017-12-22
4
S
0
3529
20.50
D
0
D
Stock Option (right to buy)
4.21
2017-12-22
4
M
0
3529
0.00
D
2026-04-29
Common Stock
3529
33273
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017.
The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date.
/s/ Thomas P. O'Neil, Attorney-in-Fact
2017-12-26